[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metagenome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metagenome":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":38,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100628100","probiotic-research-open-label-functional-intervention-and-longitudinal-evaluation-in-healthy-adults-100628100",false,"NCT07457242","Probiotic Research: Open-label Functional Intervention and Longitudinal Evaluation in Healthy Adults","PROFILE","Inclusion Criteria:\n\n* Aged 18 years or older at the time of providing informed consent.\n* In generally good health, with no known medical conditions that could interfere with the aims of the study or participant safety, as judged by self-report and screening questionnaire.\n* No history of significant psychiatric or neurological illness\n* Ability to complete study specific tasks, including:\n* Daily oral intake of a probiotic capsule\n* Self-collection of stool samples\n* Completion of online questionnaires and simple cognitive tasks\n* Able to read, understand, and communicate in English, in order to give informed consent and follow study instructions.\n* Access to the internet and a suitable device (e.g., smartphone, tablet, or computer) for completing online aspects of the study.\n\nExclusion Criteria:\n\n* Participants will be excluded from the study if any of the following criteria apply:\n* Use of any systemic antibiotic or systemic immunosuppressive medication within the past 8 weeks, including but not limited to:\n* β-lactam antibiotics, macrolides, tetracyclines, fluoroquinolones, aminoglycosides, glycopeptides, sulfonamides, antimycobacterial agents, systemic antifungals or antivirals\n* Use of any systemic immunosuppressants within the past 16 weeks, including, but not limited to:\n* Systemic corticosteroids, conventional immunosuppressants, biologic immunomodulators, targeted synthetic immunosuppressants, cytotoxic chemotherapy, or transplant-related immunosuppression.\n* A longer exclusion window is applied for systemic immunosuppressive therapies due to their prolonged and potentially lasting effects on immune function and gut microbial composition compared with systemic antibiotics.\n* Participants who commence systemic antibiotics or immunosuppressive therapy after enrolment will not be withdrawn from safety monitoring but will stop the supplement and will not continue the intervention phase of the study. With participant consent, data collected may still be used.\n* Major gastrointestinal disease or surgery:\n* Any history of significant gastrointestinal disease or surgery that may alter gut microbiome composition, immune function, or nutrient absorption, including but not limited to inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis); coeliac disease or other chronic malabsorptive disorders; chronic liver, biliary, or pancreatic disease; moderate-to-severe or unstable irritable bowel syndrome; gastrointestinal malignancy; chronic gastrointestinal motility disorders; recurrent Clostridioides difficile infection; or any major gastrointestinal surgery such as bowel resection, bariatric surgery, colectomy, ileostomy or colostomy. Prior appendectomy or cholecystectomy alone is not exclusionary.\n* Current pregnancy or development of pregnancy, breastfeeding\n* Known allergy to probiotic or compounding ingredients:\n* Vitamin D3\n* Isomaltooligosaccharide\n* Yeast extract",true,"ALL","18 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a pre-post, open-label cohort study designed to investigate how a food-grade probiotic supplement affects biological measurements and wellbeing in healthy adults. Participants will take one capsule daily for either 1 month or 6 months.\n\nDuring the study, participants will complete online cognitive tasks and provide blood and stool samples collected during home visits by trained staff. The samples will be analysed to explore changes in gut bacteria and other biological markers.\n\nThis study aims to understand whether the supplement is well tolerated and whether measurable biological changes occur. The study does not involve any experimental drugs or invasive procedures beyond blood sampling and stool collection, and participants will not be asked to change any current prescribed medications or treatments; with eligibility exclusions applying for recent antibiotics or immunosuppressants. The supplement is being studied for research purposes only and is not intended to diagnose, treat, or prevent disease. Participants will be invited to participate in a follow-up visit to assess long-term effects.",[27,28,29,30,31,32,33,34,35,36,37],"Cognition","Multiomics","Microbiome Analysis","Metabolome","Proteome","Metagenome","Probiotics Supplement","Gut-brain Axis","Pilot Study","Adult","Sleep",[39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Probiotics","Dietary Supplements","Microbiome","Multi-omics","Metabolomics","Proteomics","Mitochondrial Function","Cellular Metabolism","Short-Chain Fatty Acids","Bioinformatics","Healthy volunteers","Pilot study","feasibility study","cognitive function","mental health","NOT_YET_RECRUITING","2026-03-03",{"date":57,"type":58},"2026-03-09","ACTUAL",{"date":60,"type":21},"2026-07-01",{"date":62,"type":21},"2027-07-01",{"name":64,"class":65},"OneCarbon","INDUSTRY",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":73,"targetDuration":75,"studyType":76,"phases":4,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100604796","comprehensive-analysis-of-gut-microbiota-signatures-in-metastatic-colorectal-cancer-100604796","NCT07154173","Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Pathologically confirmed colorectal cancer\n* Clearly defined clinical staging: including imaging or pathologically confirmed metastatic colorectal cancer (stage M1) and colorectal cancer without distant metastasis (stage M0)\n* Expected survival ≥ 3 months\n* Voluntary participation and signed informed consent\n\nExclusion Criteria:\n\n* Use of probiotics, antibiotics, or immunosuppressive agents within 1 month before surgery\n* Preoperative complete intestinal obstruction or gastrointestinal perforation\n* Intraoperative gastrointestinal perforation or tumor rupture\n* Previous history of gastrointestinal surgery (excluding colorectal cancer surgery, appendectomy, and cholecystectomy) or concurrent severe gastrointestinal diseases such as inflammatory bowel disease\n* Concurrent active systemic immune or infectious diseases, including severe allergies, rheumatoid arthritis, systemic lupus erythematosus, viral hepatitis, acquired immunodeficiency syndrome, etc.\n* Concurrent unhealed primary malignant tumors\n* Severe organ dysfunction or failure\n* Other conditions deemed unsuitable for this study by the investigator","75 Years",{"count":74,"type":21},300,"1 Year","OBSERVATIONAL","Colorectal cancer (CRC) is one of the most common and deadly cancers worldwide. About 1 in 4 people with CRC already have cancer spread (metastasis) when first diagnosed, and about half develop spread during their illness. Recent research shows that bacteria living in the gut and even within tumors might play an important role in how cancer spreads.\n\nThe goal of this study is to better understand how bacteria might influence the spread of colorectal cancer. The main questions the investigators aim to answer are:\n\nAre there differences in bacteria between people whose cancer has spread and those whose cancer has not spread? Could certain bacteria help predict which cancers might spread?\n\nTo answer these questions, the investigators will:\n\nCollect different types of samples from participants:\n\nTumor tissue Normal tissue near the tumor Tissue from where cancer has spread Stool samples before surgery Study the bacteria in these samples using advanced testing methods Compare bacterial patterns between different groups\n\nPeople can take part in this study if they:\n\nAre between 18 and 75 years old Have colorectal cancer confirmed by doctors Have not taken antibiotics recently Do not have immune system problems\n\nThis research may help us:\n\nUnderstand why some colorectal cancers spread Find new ways to predict which cancers might spread Develop better treatments for colorectal cancer",[79,80,81,32],"Rectal Neoplasms","Colon Neoplasms","Microbiota",[83,84,85,86],"rectal neoplasms","colon neoplasms","microbiota","metagenomics","RECRUITING","2025-12-26",{"date":90,"type":58},"2025-12-31",{"date":92,"type":58},"2025-01-01",{"date":94,"type":21},"2026-12-31",{"name":96,"class":97},"Sixth Affiliated Hospital, Sun Yat-sen University","OTHER",1]